Tag:

Ariad Pharmaceuticals

Latest Headlines

Latest Headlines

Merck scuttles a $700M-plus Ariad deal and hands back a once-vaunted cancer drug

Back in 2010, Ariad Pharmaceuticals' ridaforolimus was a promising cancer therapy worth up to $700 million in the eyes of Merck. Now, in light of an FDA rejection and some dimming development prospects, Merck has quietly washed its hands of the drug, handing it back to its former partner.

Ariad lets an activist through the gate as shaky buyout rumors linger

Ariad Pharmaceuticals has appointed a former Carl Icahn acolyte to its board of directors, giving in to the activist investor after downing a poison pill to fend off any hostile advances. Now, amid some loosely founded chatter about its M&A potential, the bruised biotech could be in for another shakeup.

Buzz: Back from the ER, a wounded Ariad spurs a fresh round of takeover rumors

Market rumors about a possible biotech buyout are usually triggered by research and marketing success. In Ariad's case, mere survival sufficed.

Welcome back, Ariad: Iclusig returns after a cold winter

Last year, Ariad Pharmaceuticals watched more than $2.5 billion melt off its market cap when the cancer-fighting Iclusig began a downward spiral that would eventually remove it from the market. But now begins the rebuilding project, as the Cambridge, MA, drugmaker has relaunched its sole product with a lot of ground to make up.

Ariad storms back with an FDA nod to get Iclusig back on the U.S. market

Losing more than $2.5 billion in market value didn't kill Ariad Pharmaceuticals, and now the biotech is set to relaunch the once-spurned cancer drug Iclusig in the U.S. as the FDA has approved a new label and indication for the company's only product.

Ariad faces fresh woe as EMA takes a harder look at Iclusig

Ariad Pharmaceuticals seemed to dodge a bullet last month when the European Medicines Agency chose not to follow its U.S. counterpart, letting the troubled Iclusig stay on the market. Now, the regulator is reopening the books on Ariad's cancer drug, reviving concerns about the company's sole product and sending its shares down about 10%.

UPDATED: Ariad canning 40% of U.S. workers as troubled Iclusig gathers dust

Ariad Pharmaceuticals is letting go of nearly half its U.S. staff just a week after pulling its leukemia drug Iclusig from the market at the FDA's request, an unsurprising next step in what has been a monthlong downward spiral for the Massachusetts biotech.

Flailing Ariad swallows poison pill to fend off takeovers

With a plummeting share price and grim prospects for its lead drug, Ariad Pharmaceuticals is adopting a shareholder rights plan to deter would-be corporate raiders, a move to protect what little value it has left.

UPDATED: Ariad shares plunge again after safety fears force halt to Iclusig sales

Shares of badly battered Ariad Pharmaceuticals took a fresh dive this morning after the biotech reported that it is jerking its leukemia drug Iclusig from the market, two weeks after the drug developer opted to shutter its Phase III confirmatory study after seeing evidence of an elevated risk of blood clots among patients.

Ariad's Iclusig disaster puts HQ move in jeopardy

Ariad Pharmaceuticals' October fall from grace has wiped almost $3 billion from the company's market cap, and now the beleaguered drugmaker is putting on hold its plans to move into a built-to-suit new headquarters in Cambridge, MA's biotech hub.